Concepts (134)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Adiponectin | 3 | 2017 | 55 | 0.910 |
Why?
|
| Peptide Library | 4 | 2014 | 25 | 0.770 |
Why?
|
| RNA, Small Interfering | 2 | 2013 | 409 | 0.690 |
Why?
|
| Bacteriophages | 5 | 2013 | 44 | 0.680 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2017 | 128 | 0.620 |
Why?
|
| Cell Adhesion Molecules, Neuronal | 1 | 2017 | 13 | 0.620 |
Why?
|
| Breast Neoplasms | 7 | 2022 | 1502 | 0.610 |
Why?
|
| Nonmuscle Myosin Type IIA | 1 | 2017 | 3 | 0.600 |
Why?
|
| Nonmuscle Myosin Type IIB | 1 | 2017 | 5 | 0.600 |
Why?
|
| Liposomes | 4 | 2011 | 118 | 0.550 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2014 | 295 | 0.540 |
Why?
|
| Pancreatic Neoplasms | 2 | 2014 | 111 | 0.520 |
Why?
|
| Drug Delivery Systems | 2 | 2014 | 202 | 0.510 |
Why?
|
| Nanomedicine | 2 | 2014 | 35 | 0.500 |
Why?
|
| Viral Fusion Proteins | 2 | 2011 | 4 | 0.480 |
Why?
|
| Adipocytes | 2 | 2017 | 58 | 0.410 |
Why?
|
| Antineoplastic Agents | 4 | 2014 | 803 | 0.400 |
Why?
|
| Viral Proteins | 1 | 2013 | 174 | 0.390 |
Why?
|
| Nanoparticles | 2 | 2013 | 318 | 0.390 |
Why?
|
| Gene Transfer Techniques | 1 | 2010 | 47 | 0.370 |
Why?
|
| Oligopeptides | 1 | 2010 | 102 | 0.360 |
Why?
|
| Phosphatidylinositol 4,5-Diphosphate | 1 | 2006 | 6 | 0.280 |
Why?
|
| Endothelin-1 | 1 | 2006 | 55 | 0.270 |
Why?
|
| Actins | 1 | 2006 | 148 | 0.260 |
Why?
|
| Cell Line, Tumor | 7 | 2014 | 2231 | 0.260 |
Why?
|
| Neoplasms | 3 | 2024 | 1103 | 0.260 |
Why?
|
| Pancreatic Cyst | 1 | 2023 | 4 | 0.230 |
Why?
|
| Pancreas | 1 | 2023 | 35 | 0.230 |
Why?
|
| Doxorubicin | 3 | 2014 | 84 | 0.230 |
Why?
|
| Protein Transport | 3 | 2014 | 302 | 0.220 |
Why?
|
| 3T3-L1 Cells | 2 | 2017 | 16 | 0.220 |
Why?
|
| Capsid Proteins | 3 | 2012 | 67 | 0.200 |
Why?
|
| Dog Diseases | 1 | 2021 | 30 | 0.200 |
Why?
|
| Drug Carriers | 2 | 2011 | 125 | 0.170 |
Why?
|
| Humans | 15 | 2024 | 37093 | 0.160 |
Why?
|
| Amino Acid Sequence | 4 | 2014 | 1180 | 0.150 |
Why?
|
| Disease-Free Survival | 1 | 2017 | 113 | 0.150 |
Why?
|
| Thiazolidines | 1 | 2017 | 5 | 0.150 |
Why?
|
| Female | 11 | 2022 | 20969 | 0.150 |
Why?
|
| Molecular Sequence Data | 4 | 2014 | 1568 | 0.150 |
Why?
|
| MicroRNAs | 1 | 2022 | 426 | 0.150 |
Why?
|
| Signal Transduction | 1 | 2006 | 1908 | 0.150 |
Why?
|
| Biological Transport | 1 | 2017 | 185 | 0.140 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2022 | 807 | 0.140 |
Why?
|
| Neoplasm Metastasis | 1 | 2017 | 219 | 0.140 |
Why?
|
| Hep G2 Cells | 2 | 2013 | 51 | 0.130 |
Why?
|
| Structure-Activity Relationship | 1 | 2017 | 409 | 0.130 |
Why?
|
| Blotting, Western | 3 | 2013 | 859 | 0.130 |
Why?
|
| Ultrasonography | 3 | 2023 | 112 | 0.130 |
Why?
|
| Mice | 4 | 2017 | 5913 | 0.120 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2017 | 1039 | 0.120 |
Why?
|
| Dogs | 2 | 2021 | 149 | 0.120 |
Why?
|
| Polyethylene Glycols | 1 | 2014 | 84 | 0.120 |
Why?
|
| Substrate Specificity | 1 | 2014 | 212 | 0.120 |
Why?
|
| Particle Size | 2 | 2011 | 215 | 0.110 |
Why?
|
| Cells, Cultured | 1 | 2017 | 1518 | 0.110 |
Why?
|
| Microscopy, Atomic Force | 1 | 2013 | 60 | 0.110 |
Why?
|
| RNA-Binding Proteins | 2 | 2012 | 146 | 0.110 |
Why?
|
| Genetic Vectors | 1 | 2013 | 158 | 0.110 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2014 | 222 | 0.100 |
Why?
|
| Animals | 6 | 2021 | 15081 | 0.100 |
Why?
|
| Cell Proliferation | 1 | 2017 | 1198 | 0.100 |
Why?
|
| Peptides | 2 | 2012 | 320 | 0.100 |
Why?
|
| Microscopy, Fluorescence | 1 | 2013 | 252 | 0.100 |
Why?
|
| Body Composition | 1 | 2012 | 162 | 0.100 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2013 | 448 | 0.100 |
Why?
|
| Immunomagnetic Separation | 1 | 2010 | 5 | 0.100 |
Why?
|
| Magnetics | 1 | 2010 | 36 | 0.090 |
Why?
|
| Static Electricity | 1 | 2010 | 78 | 0.090 |
Why?
|
| Organ Specificity | 1 | 2010 | 129 | 0.090 |
Why?
|
| Biological Assay | 1 | 2010 | 59 | 0.090 |
Why?
|
| Apoptosis | 1 | 2017 | 1398 | 0.090 |
Why?
|
| Gene Silencing | 1 | 2010 | 151 | 0.090 |
Why?
|
| Biosensing Techniques | 1 | 2010 | 86 | 0.090 |
Why?
|
| Repressor Proteins | 1 | 2010 | 249 | 0.080 |
Why?
|
| Body Mass Index | 1 | 2012 | 854 | 0.080 |
Why?
|
| Transcription, Genetic | 1 | 2010 | 578 | 0.080 |
Why?
|
| DNA-Binding Proteins | 1 | 2010 | 539 | 0.070 |
Why?
|
| Transcription Factors | 1 | 2010 | 681 | 0.070 |
Why?
|
| Down-Regulation | 1 | 2006 | 435 | 0.060 |
Why?
|
| Lymphatic Metastasis | 1 | 2003 | 65 | 0.060 |
Why?
|
| Surgical Flaps | 1 | 2003 | 4 | 0.060 |
Why?
|
| Mammaplasty | 1 | 2003 | 8 | 0.060 |
Why?
|
| Mastectomy | 1 | 2003 | 15 | 0.060 |
Why?
|
| Biology | 1 | 2022 | 16 | 0.050 |
Why?
|
| Cell Line | 1 | 2006 | 1354 | 0.050 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2023 | 214 | 0.050 |
Why?
|
| Genomics | 1 | 2024 | 223 | 0.050 |
Why?
|
| Prostatic Neoplasms | 1 | 2010 | 935 | 0.050 |
Why?
|
| Proteomics | 1 | 2022 | 325 | 0.050 |
Why?
|
| Algorithms | 1 | 2023 | 465 | 0.050 |
Why?
|
| Cytokines | 1 | 2024 | 602 | 0.040 |
Why?
|
| RNA, Messenger | 1 | 2022 | 1207 | 0.040 |
Why?
|
| Prospective Studies | 2 | 2012 | 1378 | 0.030 |
Why?
|
| Cachexia | 1 | 2012 | 6 | 0.030 |
Why?
|
| Aged, 80 and over | 2 | 2012 | 2379 | 0.030 |
Why?
|
| Protein Engineering | 1 | 2012 | 44 | 0.030 |
Why?
|
| Anthropometry | 1 | 2012 | 97 | 0.030 |
Why?
|
| Antibodies | 1 | 2012 | 141 | 0.030 |
Why?
|
| Weight Loss | 1 | 2012 | 131 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2012 | 325 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2012 | 259 | 0.020 |
Why?
|
| NIH 3T3 Cells | 1 | 2011 | 61 | 0.020 |
Why?
|
| Phosphoproteins | 1 | 2012 | 163 | 0.020 |
Why?
|
| Elastic Modulus | 1 | 2010 | 17 | 0.020 |
Why?
|
| Adipose Tissue | 1 | 2012 | 177 | 0.020 |
Why?
|
| Equipment Failure Analysis | 1 | 2010 | 41 | 0.020 |
Why?
|
| Coculture Techniques | 1 | 2011 | 101 | 0.020 |
Why?
|
| Freeze Fracturing | 1 | 2010 | 1 | 0.020 |
Why?
|
| Microscopy, Electron | 1 | 2011 | 209 | 0.020 |
Why?
|
| Surface Properties | 1 | 2011 | 130 | 0.020 |
Why?
|
| Drug Stability | 1 | 2011 | 116 | 0.020 |
Why?
|
| Equipment Design | 1 | 2010 | 124 | 0.020 |
Why?
|
| Drug Compounding | 1 | 2011 | 76 | 0.020 |
Why?
|
| Rhodamines | 1 | 2010 | 21 | 0.020 |
Why?
|
| Muscle, Skeletal | 1 | 2012 | 282 | 0.020 |
Why?
|
| Spectrometry, Fluorescence | 1 | 2011 | 208 | 0.020 |
Why?
|
| Prognosis | 1 | 2012 | 739 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2012 | 661 | 0.020 |
Why?
|
| Lipids | 1 | 2011 | 235 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2012 | 885 | 0.020 |
Why?
|
| Middle Aged | 3 | 2012 | 10129 | 0.020 |
Why?
|
| Adult | 3 | 2012 | 11712 | 0.020 |
Why?
|
| Radioimmunoassay | 1 | 2007 | 65 | 0.020 |
Why?
|
| Adipose Tissue, White | 1 | 2007 | 14 | 0.020 |
Why?
|
| Aged | 2 | 2012 | 6741 | 0.020 |
Why?
|
| Male | 3 | 2012 | 20025 | 0.020 |
Why?
|
| Sequence Alignment | 1 | 2007 | 265 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2007 | 623 | 0.020 |
Why?
|
| Axilla | 1 | 2003 | 4 | 0.010 |
Why?
|
| False Positive Reactions | 1 | 2003 | 26 | 0.010 |
Why?
|
| Biopsy, Needle | 1 | 2003 | 60 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2003 | 562 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2003 | 2026 | 0.010 |
Why?
|